Directorate Change

RNS Number : 4458R

Uniphar PLC

30 June 2020

 

Directorate Change

Dublin, London | 30 June 2020

Uniphar plc (the "Company") wishes to announce that, in line with the Board's stated objective to transition to a Board composition that meets the independence requirements of the UK Corporate Governance Code within three years from IPO, Mark Moran will step down from the Board on 1 September 2020. Mark joined the Board as a representative of the Sisk Family on the acquisition of Sisk Healthcare Group in 2018 and resigns in line with the appointment rights granted in connection with that acquisition. Ger Penny, also appointed as a Sisk Family representative at the time of the Sisk acquisition, will continue on the board as a Non-Executive Director.

Maurice Pratt, Chairman of Uniphar plc, commented:

"On behalf of the Board, I would like to take this opportunity to thank Mark for the support and commitment he has shown to the Board over the last two years. Mark's experience and insights were a great support to the Board in preparing for, and in the months since, the successful IPO of Uniphar in 2019, and we wish him well with his future endeavours."

--- ENDS ---

For further details contact:

Uniphar	[phone]
Brian O'Shaughnessy
Group Director of Corporate Development	[e-mail]
Davy	[phone]
(Joint Broker, Nominated Adviser and Euronext Growth Adviser)
Fergal Meegan
Barry Murphy
Tom Tynan
RBC Capital Markets (Joint Broker)	[phone]
Darrell Uden
Jonathan Hardy
Jamil Miah
Q4 PR	[phone] or
(Public Relations Adviser to Uniphar)	[phone]
Iarla Mongey

About Uniphar plc

Headquartered in Dublin, Ireland, Uniphar is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,200, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US.
 

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.
 

Commercial & Clinical  

In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, the Benelux and the Nordics, the Group is growing with clients to provide pan-European solutions. Uniphar have built a fully integrated multi-channel solution that is supported by highly experienced, clinically trained teams to deliver exceptional outcomes for all clients.

Product Access  

In Product Access the Group is growing two distinct service offerings: 1) "On-Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions to more than 160 markets globally.

Supply Chain & Retail  

Uniphar is an established market leader in Ireland with c50% supply chain market share supported by a network of 287 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the assets and infrastructure are utilised for the benefit of the growth divisions.

 

END

 

 

BOAEANKNADDEEFA